Home La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
 

Keywords :   


La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)

2014-07-30 09:57:01| drugdiscoveryonline Home Page

La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial

Tags: data positive oral pharmaceutical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11contactglove tundratracker
23.11
23.11RUSSELUNO
23.11C282 800yd IP54
23.11X-FLY4 27.5
23.118
23.11 (1~40)
23.1101DVDBOX
More »